Q2 2026 Hydreight Technologies Inc Earnings Call Transcript
Key Points
- Record Q2 revenue of $28 million, up over 400% year-over-year and 12.5% sequentially, with strong profitability (adjusted EBITDA of $3.2 million and net income of $2.5 million).
- Broad-based growth across all business segments, including a significant ramp in the direct-to-consumer platform (VST-H1) to $22.8 million in revenue and a 30% year-over-year increase in mobile medical services.
- Regulatory tailwinds from FDA recommendations to add six peptides to the national compounding list, which could open new revenue opportunities for the platform's existing infrastructure.
- Strong balance sheet with $20 million in cash and $35.1 million in working capital, providing ample capacity for strategic investments in pharmacy partnerships and product line expansions.
- Reaffirmed full-year guidance of $150 million in revenue and 15-17% adjusted EBITDA margin, supported by visible drivers and a large existing partner base.
- Gross margin declined to 19.4% from 36% a year ago due to a shift in revenue mix toward lower-margin pharmacy sales, with pharmacy margin at 14% in Q2, down from 17% in Q1.
- Adjusted EBITDA margin decreased to 11.5% from 13.1% in Q1, reflecting pricing concessions, lower GLP-1 medication costs, and increased growth spending.
- Significant working capital deployment of $8.7 million in H1, tied to pharmacy prepayments and receivables, which may pressure cash flow in the near term.
- Dependence on regulatory approvals for new peptides, which are still recommendations and not final rules, creating uncertainty about the timing and scale of future revenue.
- Pricing pressure in the GLP-1 sector and competition from non-compliant pharmacies have compressed margins, though the company expects normalization as regulations tighten.
(audio in progress) Before we begin, please note that today's remarks contain forward-looking statements within the meaning of applicable Canadian securities law. Actual results may differ materially from those expressed or implied today. For a discussion of the assumptions and risk factors involved, please refer to the company's MD&A and other continuous disclosure documents filed on SEDAR+.
Today's discussion also references certain non-GAAP financial measures, including adjusted revenue, adjusted gross margin and adjusted EBITDA. The consolidations to the most comparable GAAP measures are provided in the company's MD&A. And we're just going to give a few moments here? Well, I see some more people just joining in before I do turn it over, just one moment and we will just pass it off to CEO, Shane Madden.
Thank you, Abbey. Good morning, and thank you for joining us for everybody, three months ago, we stood in front of you and told you that our record first quarter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
